Virax Biolabs Group Limited (NASDAQ:VRAX) Short Interest Update

Virax Biolabs Group Limited (NASDAQ:VRAX) was the recipient of a significant growth in short interest in October. As of October 31st, there was short interest totalling 446,500 shares, a growth of 92.6% from the October 15th total of 231,800 shares. Based on an average daily volume of 6,030,000 shares, the short-interest ratio is currently 0.1 days. Approximately 11.0% of the shares of the company are short sold.

Virax Biolabs Group Stock Performance

Shares of VRAX stock traded down $0.09 during trading on Friday, reaching $1.81. 74,772 shares of the company’s stock traded hands, compared to its average volume of 2,221,239. The firm’s 50-day moving average is $2.19 and its 200 day moving average is $1.86. Virax Biolabs Group has a 1 year low of $0.60 and a 1 year high of $9.00.

Virax Biolabs Group Company Profile

Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name.